Kintara Therapeutics Announces Fiscal 2022 Financial Results and Provides Corporate UpdatePRNewsWire • 09/27/22
Kintara Therapeutics Announces Three Abstracts Have Been Accepted for the 2022 Society for Neuro-Oncology Annual MeetingPRNewsWire • 09/08/22
Kintara Therapeutics Receives Study May Proceed Letter from the FDA for REM-001 for Cutaneous Metastatic Breast CancerPRNewsWire • 08/09/22
Kintara Therapeutics Enters Into Equity Purchase Agreement for Up to $20 Million with Lincoln Park CapitalPRNewsWire • 08/03/22
Kintara Therapeutics to Present at the Alliance Global Partners Summer Healthcare ConferencePRNewsWire • 06/21/22
Kintara Therapeutics Granted Fast Track Designation from the FDA for VAL-083 for Newly-Diagnosed GlioblastomaPRNewsWire • 06/15/22
Kintara Announces First European Site Activation in Switzerland in GCAR Phase 2/3 Clinical Trial for GlioblastomaPRNewsWire • 05/27/22
Kintara Therapeutics Announces Fiscal 2022 Third Quarter Financial Results and Provides Corporate UpdatePRNewsWire • 05/13/22
Kintara Announces Closing of $8.6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq RulesPRNewsWire • 04/14/22
Kintara Announces $8.6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq RulesPRNewsWire • 04/12/22
Kintara Therapeutics presents data on VAL-083 at the 2022 American Association for Cancer Research Annual MeetingProactive Investors • 04/11/22
Kintara Therapeutics Presents Data at the 2022 American Association for Cancer Research Annual MeetingPRNewsWire • 04/11/22
Kintara Therapeutics to Present at the Maxim Group 2022 Virtual Growth ConferencePRNewsWire • 03/22/22
Kintara Therapeutics Announces Data Presentation at the 2022 American Association for Cancer Research Annual MeetingPRNewsWire • 03/15/22
Kintara Therapeutics Announces Fiscal 2022 Second Quarter Financial Results and Provides Corporate UpdatePRNewsWire • 02/11/22